Ferhan Qureshi

Serum biomarkers of brain atrophy in MS 4:59
Serum biomarkers of brain atrophy in MS
Ferhan Qureshi • 27 Feb 2023
Serum proteins associated with glial cell injury, MRI measures & neuropsychological outcomes in MS 4:03
Serum proteins associated with glial cell injury, MRI measures & neuropsychological outcomes in MS
Ferhan Qureshi • 27 Feb 2023
Real-world use of the MSDA test: a case series 3:54
Real-world use of the MSDA test: a case series
Ferhan Qureshi • 27 Feb 2023
Differential diagnosis of MS patients using serum proteomics: disease state & MS subtype 2:13
Differential diagnosis of MS patients using serum proteomics: disease state & MS subtype
Ferhan Qureshi • 26 Oct 2022
MSDA test classifies relapsing MS patients based on steroid response and disease activity status 1:04
MSDA test classifies relapsing MS patients based on steroid response and disease activity status
Ferhan Qureshi • 26 Oct 2022
Blood serum proteome correlates of MS disease progression: a 5-year longitudinal study 1:38
Blood serum proteome correlates of MS disease progression: a 5-year longitudinal study
Ferhan Qureshi • 26 Oct 2022
Validation of the MSDA test in plasma 1:18
Validation of the MSDA test in plasma
Ferhan Qureshi • 26 Oct 2022
MSDA validation test algorithm – the benefits to clinical practice 1:00
MSDA validation test algorithm – the benefits to clinical practice
Ferhan Qureshi • 24 Feb 2022
Clinical validation of the MSDA test 1:52
Clinical validation of the MSDA test
Ferhan Qureshi • 24 Feb 2022
An independent focal inflammation cohort – performance of the MSDA validation test algorithm 1:37
An independent focal inflammation cohort – performance of the MSDA validation test algorithm
Ferhan Qureshi • 24 Feb 2022
A multivariate proteomic assay for disease activity assessments in MS 2:48
A multivariate proteomic assay for disease activity assessments in MS
Ferhan Qureshi • 24 Feb 2022
The content of VJNeurology is intended for healthcare professionals